About LysM and putative peptidoglycan-binding domain-containing protein 2
LysM and putative peptidoglycan-binding domain-containing protein 2 (LYSMD2) is a protein
from Homo sapiens identified by UniProt accession
Q8IV50, 215 residues long.
MolForge cross-references it against 0 known binders and
32 disease associations.
Target properties
| Protein name | LysM and putative peptidoglycan-binding domain-containing protein 2 |
|---|
| UniProt accession | Q8IV50 |
|---|
| Gene | LYSMD2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 215 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (32)
Diseases linked to this target (Open Targets).
- mean reticulocyte volume · score 0.18
- developmental and epileptic encephalopathy · score 0.12
- developmental and epileptic encephalopathy, 13 · score 0.12
- body mass index · score 0.10
- body height · score 0.10
- cortical surface area measurement · score 0.08
- lean body mass · score 0.08
- intelligence · score 0.07
- body fat percentage · score 0.07
- self reported educational attainment · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IV50-F1 | alphafold | PREDICTED | 66.94 | — |
Amino-acid sequence (215 residues)
MADSSPALSL REGGPRAPRP SAPSPPPRSR SGSESEEAEL SLSLARTKTR SYGSTASVRA PLGAGVIERH VEHRVRAGDT LQGIALKYGV TMEQIKRANK LFTNDCIFLK KTLNIPVISE KPLLFNGLNS IDSPENETAD NSFSQEEEPV VAGEDLPPPS PQESDVQPVQ PEEVSARDFL QRLDLQIKLS TQAAKKLKEE SRDEESPYAT SLYHS
Explore LysM and putative peptidoglycan-binding domain-containing protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets